Scientific Advances in Lung Cancer 2015

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064 · see citing works

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · see citing works

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · see citing works

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works

Oncology meets immunology: the cancer-immunity cycle.

Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · see citing works

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · see citing works

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · see citing works

Comprehensive molecular profiling of lung adenocarcinoma

The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732 · see citing works

The Health consequences of smoking—50 years of progress : a report of the Surgeon General

Lushniak, B. D., Samet, J. M., Pechacek, T. F., Norman, L., & Taylor, P. A. (2014) · Cited by 4,990 · see citing works

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

Travis, W. D., Brambilla, E. M., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Schil, P. E. V., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,780 · see citing works

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

Goldstraw, P. G., Chansky, K., Crowley, J. J., Rami–Porta, R., Asamura, H., Eberhardt, W., Nicholson, A. G., Groome, P. A., Mitchell, A., Bolejack, V., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.09.009 · Cited by 4,616 · see citing works

The 2015 World Health Organization Classification of Lung Tumors

Travis, W. D., Brambilla, E. M., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Đačić, S., Duhig, E., Flieder, D. B., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000630 · Cited by 4,532 · see citing works

Comprehensive genomic characterization of squamous cell lung cancers

The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994 · see citing works

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours

Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655 · see citing works

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756 · see citing works

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642 · see citing works

Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement

Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2013) · Annals of Internal Medicine · doi:10.7326/m13-2771 · Cited by 2,642 · see citing works

Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer

Timmerman, R. D. (2010) · JAMA · doi:10.1001/jama.2010.261 · Cited by 2,536 · see citing works

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers

Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454 · see citing works

Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer

The International Adjuvant Lung Cancer Trial Collaborative Group (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031644 · Cited by 2,334 · see citing works

Comprehensive genomic profiles of small cell lung cancer

George, J., Lim, J. S., Jang, S. J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X. L., Fernandez‐Cuesta, L., Bosco, G., et al. (2015) · Nature · doi:10.1038/nature14664 · Cited by 2,322 · see citing works

Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer

Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964 · see citing works

Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer

Winton, T. L., Livingston, R. B., Johnson, D. H., Rigas, J. R., Johnston, M., Butts, C. A., Cormier, Y. F., Goss, G., Inculet, R., Vallières, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043623 · Cited by 1,810 · see citing works

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789 · see citing works

DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

Olaussen, K. A., Dunant, A., Fouret, P. J., Brambilla, E. M., André, F., Haddad, V., Clermont, E., Filipits, M., Pirker, R., Popper, H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060570 · Cited by 1,725 · see citing works

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724 · see citing works

Survival of Patients with Stage I Lung Cancer Detected on CT Screening

The International Early Lung Cancer Action Program Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060476 · Cited by 1,719 · see citing works

WHO classification of tumours of the lung, pleura, thymus and heart

Travis, W. D. (2015) · International Agency for Research on Cancer eBooks · Cited by 1,672 · see citing works

The IASLC Lung Cancer Staging Project: Proposals for Revision of the M Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification of Lung Cancer

Postmus, P. E., Brambilla, E. M., Chansky, K., Crowley, J. J., Goldstraw, P. G., Patz, E. F., & Yokomise, H. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31811f4703 · Cited by 1,593 · see citing works

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

Douillard, J., Rosell, R., Lena, M. D., Carpagnano, F., Ramlau, R., González-Larriba, J. L., Grodzki, T., Pereira, J. R., Groumellec, A. L., Lorusso, V., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70804-x · Cited by 1,573 · see citing works

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,489 · see citing works

Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

Chang, J. Y., Senan, S., Paul, M. A., Mehran, R. J., Louie, A. V., Balter, P., Groen, H. J. M., McRae, S. E., Widder, J., Feng, L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70168-3 · Cited by 1,462 · see citing works

Probability of Cancer in Pulmonary Nodules Detected on First Screening CT

McWilliams, A. M., Tammemägi, M. C., Mayo, J. R., Roberts, H. C., Liu, G., Soghrati, K., Yasufuku, K., Martel, S., Laberge, F., Gingras, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214726 · Cited by 1,425 · see citing works

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415 · see citing works

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

Peifer, M., Fernandez‐Cuesta, L., Sos, M. L., George, J., Seidel, D., Kasper, L. H., Plenker, D., Leenders, F., Sun, R., Zander, T., et al. (2012) · Nature Genetics · doi:10.1038/ng.2396 · Cited by 1,390 · see citing works

RET, ROS1 and ALK fusions in lung cancer

Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2658 · Cited by 1,320 · see citing works

The National Lung Screening Trial: Overview and Study Design

National Lung Screening Trial Research Team (2010) · Radiology · doi:10.1148/radiol.10091808 · Cited by 1,280 · see citing works

50-Year Trends in Smoking-Related Mortality in the United States

Thun, M. J., Carter, B. D., Feskanich, D., Freedman, N. D., Prentice, R., Lopez, A. D., Hartge, P., & Gapstur, S. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1211127 · Cited by 1,177 · see citing works

Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers

Govindan, R., Ding, L., Griffith, M., Subramanian, J., Dees, N. D., Kanchi, K., Maher, C. A., Fulton, R. S., Fulton, L., Wallis, J. W., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.024 · Cited by 1,144 · see citing works

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

Rudin, C. M., Durinck, S., Stawiski, E. W., Poirier, J. T., Modrusan, Z. D., Shames, D. S., Bergbower, E. A. S., Guan, Y., Shin, J., Guillory, J., et al. (2012) · Nature Genetics · doi:10.1038/ng.2405 · Cited by 1,066 · see citing works

Selection Criteria for Lung-Cancer Screening

Tammemägi, M. C., Katki, H. A., Hocking, W. G., Church, T. R., Caporaso, N. E., Kvale, P. A., Chaturvedi, A. K., Silvestri, G. A., Riley, T. L., Commins, J. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211776 · Cited by 1,023 · see citing works

Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases

Yoshizawa, A., Motoi, N., Riely, G. J., Sima, C. S., Gerald, W. L., Kris, M. G., Park, B. J., Rusch, V. W., & Travis, W. D. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.232 · Cited by 974 · see citing works

British Thoracic Society guidelines for the investigation and management of pulmonary nodules: accredited by NICE

Callister, M. E. J., Baldwin, D., Akram, A. R., Barnard, S., Cane, P., Draffan, J., Franks, K., Gleeson, F. V., Graham, R., Malhotra, P. S., et al. (2015) · Thorax · doi:10.1136/thoraxjnl-2015-207168 · Cited by 970 · see citing works

Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis

Levit, L. A., Balogh, E. P., Nass, S. J., & Ganz, P. A. (2014) · Cited by 956 · see citing works

Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

Skoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936 · see citing works

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options

Schnipper, L. E., Davidson, N. E., Wollins, D. S., Tyne, C. A., Blayney, D. W., Blum, D., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6706 · Cited by 918 · see citing works

Anchored multiplex PCR for targeted next-generation sequencing

Zheng, Z., Liebers, M. R., Zhelyazkova, B. H., Cao, Y., Panditi, D., Lynch, K. D., Chen, J., Robinson, H. E., Shim, H. S., Chmielecki, J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3729 · Cited by 908 · see citing works

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Shaw, A. T., Yeap, B. Y., Solomon, B., Riely, G. J., Gainor, J. F., Engelman, J. A., Shapiro, G. I., Costa, D. B., Ou, S. I., Butaney, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70232-7 · Cited by 897 · see citing works

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

Lipson, D., Capelletti, M., Yelensky, R., Otto, G., Parker, A., Jarosz, M., Curran, J. A., Balasubramanian, S., Bloom, T., Brennan, K. W., et al. (2012) · Nature Medicine · doi:10.1038/nm.2673 · Cited by 869 · see citing works

KIF5B-RET fusions in lung adenocarcinoma

Kohno, T., Ichikawa, H., Totoki, Y., Yasuda, K., Hiramoto, M., Nammo, T., Sakamoto, H., Tsuta, K., Furuta, K., Shimada, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2644 · Cited by 834 · see citing works

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818 · see citing works

Management of Lung Nodules Detected by Volume CT Scanning

van Klaveren, R. J., Oudkerk, M., Prokop, M., Scholten, E. T., Nackaerts, K., Vernhout, R. M., van Iersel, C. A., van den Bergh, K. A. M., Westeinde, S. C. V. ‘., van der Aalst, C. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906085 · Cited by 817 · see citing works

The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

Rami–Porta, R., Bolejack, V., Crowley, J. J., Ball, D., Kim, J., Lyons, G., Rice, T. W., Suzuki, K., Thomas, C. F., Travis, W. D., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000559 · Cited by 751 · see citing works

The British Thoracic Society guidelines on the investigation and management of pulmonary nodules

Baldwin, D., & Callister, M. E. J. (2015) · Thorax · doi:10.1136/thoraxjnl-2015-207221 · Cited by 748 · see citing works

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., Frias, R. L., Gainor, J. F., Amzallag, A., Greninger, P., et al. (2014) · Science · doi:10.1126/science.1254721 · Cited by 708 · see citing works

The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival

Warth, A., Muley, T., Meister, M. A., Stenzinger, A., Thomas, M., Schirmacher, P., Schnabel, P. A., Budczies, J., Hoffmann, H., & Weichert, W. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2185 · Cited by 696 · see citing works

Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations

Paik, P. K., Arcila, M. E., Fara, M. G., Sima, C. S., Miller, V. A., Kris, M. G., Ladanyi, M., & Riely, G. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.1280 · Cited by 692 · see citing works

The International Association for the Study of Lung Cancer Lung Cancer Staging Project

Asamura, H., Chansky, K., Crowley, J. J., Goldstraw, P. G., Rusch, V. W., Vansteenkiste, J., Watanabe, H., Wu, Y.-L. L. C., Zieliński, M., Ball, D., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000678 · Cited by 691 · see citing works

Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas

Kadota, K., Nitadori, J., Sima, C. S., Ujiie, H., Rizk, N. P., Jones, D. R., Adusumilli, P. S., & Travis, W. D. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000486 · Cited by 681 · see citing works

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655 · see citing works

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

Shaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., Camidge, D. R., Socinski, M. A., Chiappori, A., Mekhail, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00488-x · Cited by 638 · see citing works

Does Lung Adenocarcinoma Subtype Predict Patient Survival?: A Clinicopathologic Study Based on the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Lung Adenocarcinoma Classification

Russell, P. A., Wainer, Z., Wright, G. M., Daniels, M. G., Conron, M., & Williams, R. A. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318221f701 · Cited by 624 · see citing works

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer

Vaishnavi, A., Capelletti, M., Le, A. T., Kako, S. L., Butaney, M., Ercan, D., Mahale, S., Davies, K. D., Aisner, D. L., Pilling, A. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3352 · Cited by 615 · see citing works

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

Costa, D. B., Shaw, A. T., Ou, S. I., Solomon, B., Riely, G. J., Ahn, M., Zhou, C., Shreeve, S. M., Selaru, P., Polli, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0539 · Cited by 603 · see citing works

The transcriptional landscape and mutational profile of lung adenocarcinomaPreprint

Seo, J., Ju, Y. S., Lee, W., Shin, J.-Y., Lee, J. J.-K., Bleazard, T., Lee, J., Jung, Y. J., Kim, J. O., Shin, J.-Y., et al. (2012) · Genome Research · doi:10.1101/gr.145144.112 · Cited by 589 · see citing works

Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

Ou, S. I., Ahn, J. S., Petris, L. D., Govindan, R., Yang, J. C., Hughes, B. G. M., Léna, H., Moro‐Sibilot, D., Bearz, A., Viteri, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9443 · Cited by 584 · see citing works

Frequency and Distinctive Spectrum of <i>KRAS</i> Mutations in Never Smokers with Lung Adenocarcinoma

Riely, G. J., Kris, M. G., Rosenbaum, D., Marks, J., Li, A., Chitale, D. A., Nafa, K., Riedel, E. R., Hsu, M., Pao, W., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0646 · Cited by 578 · see citing works

Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

Paik, P. K., Drilon, A. E. D. C., Fan, P., Yu, H. A., Rekhtman, N., Ginsberg, M. S., Borsu, L. A., Schultz, N. D., Berger, M. F., Rudin, C. M., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1467 · Cited by 575 · see citing works

Targeting of Low-Dose CT Screening According to the Risk of Lung-Cancer Death

Kovalchik, S. A., Tammemägi, M. C., Berg, C. D., Caporaso, N. E., Riley, T. L., Korch, M., Silvestri, G. A., Chaturvedi, A. K., & Katki, H. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301851 · Cited by 570 · see citing works

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations

Marchetti, A., Felicioni, L., Malatesta, S., Sciarrotta, M., Guetti, L., Chella, A., Viola, P., Pullara, C., Mucilli, F., & Buttitta, F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.9638 · Cited by 568 · see citing works

Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients

Cappuzzo, F., Marchetti, A., Skokan, M. C., Rossi, E., Gajapathy, S., Felicioni, L., Grammastro, M. D., Sciarrotta, M., Buttitta, F., Incarbone, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1635 · Cited by 557 · see citing works

RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer

Wang, R., Hu, H., Pan, Y., Li, Y., Ye, T., Li, C., Luo, X., Wang, L., Li, H., Zhang, Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1477 · Cited by 549 · see citing works

Cost-Effectiveness of CT Screening in the National Lung Screening Trial

Black, W. C., Gareen, I. F., Soneji, S. S., Sicks, J. D., Keeler, E. B., Aberle, D. R., Naeim, A., Church, T. R., Silvestri, G. A., Gorelick, J. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312547 · Cited by 541 · see citing works

A Phase III Randomized Trial of Lobectomy Versus Limited Resection for Small-sized Peripheral Non-small Cell Lung Cancer (JCOG0802/WJOG4607L)

Nakamura, K., Saji, H., Nakajima, R., Okada, M., Asamura, H., Shibata, T., Nakamura, S., Tada, H., & Tsuboi, M. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp156 · Cited by 524 · see citing works

Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies

Li, T., Kung, H., Mack, P. C., & Gandara, D. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3753 · Cited by 515 · see citing works

A Genomics-Based Classification of Human Lung Tumors

Thomas, R. K., Buettner, R., & Wolf, J. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006802 · Cited by 508 · see citing works

Complete resection in lung cancer surgery: proposed definition

Rami–Porta, R., Wittekind, C., & Goldstraw, P. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.01.001 · Cited by 499 · see citing works

Risk‐based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch‐Belgian randomised lung cancer multi‐slice CT screening trial (NELSON)

van Iersel, C. A., de Koning, H. J., Draisma, G., Mali, W. P. T. M., Scholten, E. T., Nackaerts, K., Prokop, M., Habbema, J. D. F., Oudkerk, M., & van Klaveren, R. J. (2006) · International Journal of Cancer · doi:10.1002/ijc.22134 · Cited by 489 · see citing works

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

Shaw, A. T., Friboulet, L., Leshchiner, I., Gainor, J. F., Bergqvist, S., Brooun, A., Burke, B. J., Deng, Y., Liu, W., Dardaei, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1508887 · Cited by 487 · see citing works

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

Kelly, K. L., Altorki, N. K., Eberhardt, W., O'Brien, M. E. R., Spigel, D. R., Crinò, L., Tsai, C., Kim, J.-H., Cho, E. K., Hoffman, P. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.8918 · Cited by 482 · see citing works

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

Thatcher, N., Hirsch, F. R., Luft, A. V., Szczęsna, A., Ciuleanu, T., Dediu, M., Ramlau, R., Galiulin, R., Bálint, B., Losonczy, G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00021-2 · Cited by 481 · see citing works

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

Zou, H. Y., Friboulet, L., Kodack, D. P., Engstrom, L. D., Li, Q., West, M., Tang, R. W., Wang, H., Tsaparikos, K. E., Wang, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.05.010 · Cited by 473 · see citing works

Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas

Drilon, A. E. D. C., Wang, L., Hasanovic, A., Suehara, Y., Lipson, D., Stephens, P. J., Ross, J. S., Miller, V. A., Ginsberg, M. S., Zakowski, M. F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0035 · Cited by 467 · see citing works

American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes

Ellis, L. M., Bernstein, D. S., Voest, E. E., Berlin, J. D., Sargent, D. J., Cortazar, P., Garrett-Mayer, E. S., Herbst, R. S., Lilenbaum, R., Sima, C. S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.8009 · Cited by 440 · see citing works

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

Ou, S. I., Kwak, E. L., Siwak, C. T., Dy, J., Bergethon, K. E., Clark, J. W., Camidge, D. R., Solomon, B., Maki, R. G., Bang, Y., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31821528d3 · Cited by 435 · see citing works

Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese Patients

Yoshizawa, A., Sumiyoshi, S., Sonobe, M., Kobayashi, M., Fujimoto, M., Kawakami, F., Tsuruyama, T., Travis, W. D., Date, H., & Haga, H. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182769aa8 · Cited by 435 · see citing works

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Soria, J.-C., Felip, E., Cobo, M., Lu, S., Syrigos, K., Lee, K. H., Göker, E., Georgoulias, V., Li, W., Isla, D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00006-6 · Cited by 433 · see citing works

Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

Awad, M. M., Katayama, R., McTigue, M. A., Liu, W., Deng, Y.-L., Brooun, A., Friboulet, L., Huang, D., Falk, M. D., Timofeevski, S. L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215530 · Cited by 421 · see citing works

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

Nicholson, A. G., Chansky, K., Crowley, J. J., Beyruti, R., Kubota, K., Turrisi, A., Eberhardt, W. E. E., van Meerbeeck, J., Rami-Porta, R., Goldstraw, P. G., et al. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.008 · Cited by 421 · see citing works

The IASLC Lung Cancer Staging Project

Eberhardt, W., Mitchell, A., Crowley, J. J., Kondo, H., Kim, Y. T., Turrisi, A. T., Goldstraw, P. G., & Rami–Porta, R. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000673 · Cited by 411 · see citing works

Annual or biennial CT screening versus observation in heavy smokers

Pastorino, U., Rossi, M., Rosato, V., Marchianò, A. V., Sverzellati, N., Morosi, C., Fabbri, A., Galeone, C., Negri, E., Sozzi, G., et al. (2012) · European Journal of Cancer Prevention · doi:10.1097/cej.0b013e328351e1b6 · Cited by 410 · see citing works

2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer

Eberhardt, W., Ruysscher, D. D., Weder, W., Pechoux, C. L., Leyn, P. D., Hoffmann, H., Westeel, V., Stahel, R. A., Felip, E., Peters, S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv187 · Cited by 400 · see citing works

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

Pless, M., Stupp, R., Ris, H.-B., Stahel, R. A., Weder, W., Thierstein, S., Gérard, M.-A., Xyrafas, A., Früh, M., Cathomas, R. L., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60294-x · Cited by 389 · see citing works

CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT

Saghir, Z., Dirksen, A., Ashraf, H., Bach, K., Brodersen, J., Clementsen, P. F., Døssing, M., Hansen, H., Kofoed, K. F., Larsen, K. R., et al. (2012) · Thorax · doi:10.1136/thoraxjnl-2011-200736 · Cited by 385 · see citing works

Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer

Sequist, L. V. D., von Pawel, J., Garmey, E. G., Akerley, W., Brugger, W., Ferrari, D., Chen, Y., Costa, D. B., Gerber, D. E., Орлов, С. В., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.0570 · Cited by 380 · see citing works

A Randomized Study of Lung Cancer Screening with Spiral Computed Tomography

Infante, M. V., Cavuto, S., Lutman, R. F., Brambilla, G., Chiesa, G., Ceresoli, G. L., Passera, E., Angeli, E., Chiarenza, M., Aranzulla, G., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200901-0076oc · Cited by 378 · see citing works

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

Sequist, L. V., Heist, R. S., Shaw, A. T., Fidias, P., Rosovsky, R., Temel, J. S., Lennes, I. T., Digumarthy, S., Waltman, B. A., Bast, E., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr489 · Cited by 370 · see citing works

Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort

Mazières, J., Zalcman, G., Crinò, L., Biondani, P., Barlési, F., Filleron, T., Dingemans, A. C., Léna, H., Monnet, I., Rothschild, S. I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3302 · Cited by 367 · see citing works

The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer

Rami–Porta, R., Bolejack, V., Giroux, D. J., Chansky, K., Crowley, J. J., Asamura, H., & Goldstraw, P. G. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000334 · Cited by 367 · see citing works

Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non–Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)

Eberhardt, W., Pöttgen, C., Gauler, T. C., Friedel, G., Veit, S., Heinrich, V., Welter, S., Budach, W., Spengler, W., Kimmich, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.6812 · Cited by 366 · see citing works

Evaluation of the Lung Cancer Risks at Which to Screen Ever- and Never-Smokers: Screening Rules Applied to the PLCO and NLST Cohorts

Tammemägi, M. C., Church, T. R., Hocking, W. G., Silvestri, G. A., Kvale, P. A., Riley, T. L., Commins, J. M., & Berg, C. D. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001764 · Cited by 353 · see citing works

Outcomes of Sublobar Resection Versus Lobectomy for Stage I Non–Small Cell Lung Cancer: A 13-Year Analysis

El-Sherif, A., Gooding, W. E., dos Santos, R. S., Pettiford, B. L., Ferson, P. F., Fernando, H. C., Urda, S. J., Luketich, J. D., & Landreneau, R. J. (2006) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2006.02.029 · Cited by 352 · see citing works

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations

Liu, X., Jia, Y., Stoopler, M. B., Shen, Y., Cheng, H., Chen, J., MANSUKHANI, M. M., Koul, S., Halmos, B., & Borczuk, A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0674 · Cited by 350 · see citing works

Nodule management protocol of the NELSON randomised lung cancer screening trial

Xu, D. M., Gietema, H. A., de Koning, H. J., Vernhout, R. M., Nackaerts, K., Prokop, M., Weenink, C., Lammers, J. J., Groen, H. J. M., Oudkerk, M., et al. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.08.006 · Cited by 345 · see citing works

Radiographically determined noninvasive adenocarcinoma of the lung: Survival outcomes of Japan Clinical Oncology Group 0201

Asamura, H., Hishida, T., Suzuki, K., Koike, T., Nakamura, K., Kusumoto, M., Nagai, K., Tada, H., Mitsudomi, T., Tsuboi, M., et al. (2013) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2012.12.047 · Cited by 345 · see citing works

Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases

Sun, Y., Ren, Y., Fang, Z., Li, C., Fang, R., Gao, B., Han, X., Tian, W., Pao, W. J., Chen, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.6038 · Cited by 334 · see citing works

Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers

Onozato, R., Kosaka, T., Kuwano, H., Sekido, Y., Yatabe, Y., & Mitsudomi, T. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181913e0e · Cited by 326 · see citing works

Impact of Micropapillary Histologic Subtype in Selecting Limited Resection vs Lobectomy for Lung Adenocarcinoma of 2cm or Smaller

Nitadori, J., Bograd, A. J., Kadota, K., Sima, C. S., Rizk, N. P., Morales, E. A., Rusch, V. W., Travis, W. D., & Adusumilli, P. S. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt166 · Cited by 326 · see citing works

Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids

Fernandez‐Cuesta, L., Peifer, M., Lu, X., Sun, R., Ozretić, L., Seidel, D., Zander, T., Leenders, F., George, J., Müller, C., et al. (2014) · Nature Communications · doi:10.1038/ncomms4518 · Cited by 313 · see citing works

Lung Cancer Risk Prediction: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Models and Validation

Tammemägi, M. C., Pinsky, P. F., Caporaso, N. E., Kvale, P. A., Hocking, W. G., Church, T. R., Riley, T. L., Commins, J. M., Oken, M. M., Berg, C. D., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr173 · Cited by 307 · see citing works

Prognostic Impact of Intra-alveolar Tumor Spread in Pulmonary Adenocarcinoma

Warth, A., Muley, T., Kossakowski, C. A., Goeppert, B. F., Schirmacher, P., Dienemann, H., & Weichert, W. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000409 · Cited by 297 · see citing works

Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches

Drilon, A., Wang, L., Arcila, M. E., Balasubramanian, S., Greenbowe, J. R., Ross, J. S., Stephens, P., Lipson, D., Miller, V. A., Kris, M. G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2683 · Cited by 274 · see citing works

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

Zou, H. Y., Li, Q., Engstrom, L. D., West, M., Appleman, V. A., Wong, K. A., McTigue, M. A., Deng, Y.-L., Liu, W., Brooun, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420785112 · Cited by 272 · see citing works

Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection

Tsao, M., Marguet, S., Teuff, G. L., Lantuéjoul, S., Shepherd, F. A., Seymour, L., Kratzke, R. A., Graziano, S. L., Popper, H., Rosell, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8335 · Cited by 269 · see citing works

Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?

Kerr, K. M., Tsao, M., Nicholson, A. G., Yatabe, Y., Wistuba, I. I., & Hirsch, F. R. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000526 · Cited by 269 · see citing works

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer

Hrustanovic, G., Olivas, V. R., Pazarentzos, E., Tulpule, A., Asthana, S., Blakely, C. M., Okimoto, R. A., Lin, L., Neel, D. S., Sabnis, A. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3930 · Cited by 267 · see citing works

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Scagliotti, G. V., von Pawel, J., Novello, S., Ramlau, R., Favaretto, A. G., Barlési, F., Akerley, W., Орлов, С. В., Santoro, A., Spigel, D. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.7317 · Cited by 264 · see citing works

Predictive Value of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma in Tumor Recurrence and Patient Survival

Hung, J., Yeh, Y., Jeng, W., Wu, K.-J., Huang, B., Wu, Y., Chou, T., & Hsu, W. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.1049 · Cited by 257 · see citing works

Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).

Camidge, D. R., Ou, S. I., Shapiro, G. I., Otterson, G. A., Villaruz, L. C., Villalona-Calero, M. A., Iafrate, A. J., Varella‐Garcia, M., Đačić, S., Cardarella, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8001 · Cited by 256 · see citing works

CT Screening for Lung Cancer: Nonsolid Nodules in Baseline and Annual Repeat Rounds

Yankelevitz, D. F., Yip, R., Smith, J. P., Liang, M., Liu, Y., Xu, D. M., Salvatore, M. M., Wolf, A., Flores, R. M., & Henschke, C. I. (2015) · Radiology · doi:10.1148/radiol.2015142554 · Cited by 254 · see citing works

Prognostic Significance of Adenocarcinoma In Situ, Minimally Invasive Adenocarcinoma, and Nonmucinous Lepidic Predominant Invasive Adenocarcinoma of the Lung in Patients With Stage I Disease

Kadota, K., Villena‐Vargas, J., Yoshizawa, A., Motoi, N., Sima, C. S., Riely, G. J., Rusch, V. W., Adusumilli, P. S., & Travis, W. D. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000134 · Cited by 251 · see citing works

NELSON lung cancer screening study

Zhao, Y. R., Xie, X., de Koning, H. J., Mali, W. P. T. M., Vliegenthart, R., & Oudkerk, M. (2011) · Cancer Imaging · doi:10.1102/1470-7330.2011.9020 · Cited by 250 · see citing works

Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400

Herbst, R. S., Gandara, D. R., Hirsch, F. R., Redman, M. W., LeBlanc, M. L., Mack, P. C., Schwartz, L. H., Vokes, E. E., Ramalingam, S. S., Bradley, J. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3473 · Cited by 245 · see citing works

The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations

Tsuta, K., Kawago, M., Inoue, E., Yoshida, A., Takahashi, F., Sakurai, H., WATANABE, S.-I. J., Takeuchi, M., Furuta, K., Asamura, H., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.06.012 · Cited by 240 · see citing works

Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial

Horeweg, N., van der Aalst, C. M., Vliegenthart, R., Zhao, Y., Xie, X., Scholten, E. T., Mali, W. P. T. M., Thunnissen, E., Weenink, C., Groen, H. J. M., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00197712 · Cited by 238 · see citing works

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

Farago, A. F., Le, L. P., Zheng, Z., Muzikansky, A., Drilon, A. E. D. C., Patel, M. R., Bauer, T. M., Liu, S. V., Ou, S. I., Jackman, D. M., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000473485.38553.f0 · Cited by 229 · see citing works

Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival

Ujiie, H., Kadota, K., Chaft, J. E., Buitrago, D., Sima, C. S., Lee, M.-C., Huang, J. G., Travis, W. D., Rizk, N. P., Rudin, C. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.9818 · Cited by 225 · see citing works

EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan

Takano, T., Fukui, T., Ohe, Y., Tsuta, K., Yamamoto, S., Nokihara, H., Yamamoto, N., Sekine, I., Kunitoh, H., Furuta, K., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7254 · Cited by 220 · see citing works

Micropapillary and solid subtypes of invasive lung adenocarcinoma: Clinical predictors of histopathology and outcome

Cha, M. J., Lee, H. Y., Lee, K. S., Jeong, J. Y., Han, J., Shim, Y. M., & Hwang, H. S. (2013) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2013.09.045 · Cited by 208 · see citing works

The Association between Smoking Abstinence and Mortality in the National Lung Screening Trial

Tanner, N. T., Kanodra, N. M., Gebregziabher, M., Payne, E., Halbert, C. H., Warren, G. W., Egede, L. E., & Silvestri, G. A. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201507-1420oc · Cited by 206 · see citing works

Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients

Kim, Y.-W., Hammerman, P. S., Kim, J., Yoon, J.-A., Lee, Y., Sun, J., Wilkerson, M. D., Pedamallu, C. S., Cibulskis, K., Yoo, Y. K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.8556 · Cited by 205 · see citing works

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort

Beau‐Faller, M., Ruppert, A.-M., Voegeli, A., Neuville, A., Meyer, N., Guérin, É., Legrain, M., Mennecier, B., Wihlm, J., Massard, G., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318168d9d4 · Cited by 201 · see citing works

Prognostic Value of the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification on Death and Recurrence in Completely Resected Stage I Lung Adenocarcinoma

Hung, J., Jeng, W., Chou, T., Hsu, W., Wu, K., Huang, B., & Wu, Y. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31828920c0 · Cited by 201 · see citing works

Expression of c‐met/HGF Receptor in Human Non‐small Cell Lung Carcinomas in vitro and in vivo and Its Prognostic Significance

Ichimura, E., Maeshima, A., Nakajima, T., & Nakamura, T. (1996) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1996.tb03111.x · Cited by 201 · see citing works

International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 Report

Field, J. K., Smith, R. A., Aberle, D. R., Oudkerk, M., Baldwin, D., Yankelevitz, D. F., Pedersen, J. H., Swanson, S., Travis, W. D., Wisbuba, I. I., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823c58ab · Cited by 184 · see citing works

Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology

Pallis, A. G., Gridelli, C., Wedding, U., Finn, C. F., Veronesi, G., Jaklitsch, M. T., Luciani, A., & O'Brien, M. E. R. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu022 · Cited by 182 · see citing works

Risk of malignancy in pulmonary nodules: A validation study of four prediction models

Al-Ameri, A., Malhotra, P., Thygesen, H. H., Plant, P. K., Vaidyanathan, S., Karthik, S., Scarsbrook, A. F., & Callister, M. E. J. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.03.018 · Cited by 180 · see citing works

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Bunn, P. A., Minna, J. D., Augustyn, A., Gazdar, A. F., Ouadah, Y., Krasnow, M. A., Berns, A. J. M., Brambilla, E. M., Rekhtman, N., Massion, P. P., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.012 · Cited by 180 · see citing works

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

Gainor, J. F., Tan, D. S.-W., Pas, T. D., Solomon, B., Ahmad, A., Lazzari, C., de Marinis, F., Spitaleri, G., Schultz, K. R., Friboulet, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3009 · Cited by 177 · see citing works

Tumor Islands in Resected Early-stage Lung Adenocarcinomas are Associated With Unique Clinicopathologic and Molecular Characteristics and Worse Prognosis

Onozato, M. L., Kovach, A. E., Yeap, B. Y., Morales‐Oyarvide, V., Klepeis, V. E., Tammireddy, S., Heist, R. S., Mark, E. J., Dias-Santagata, D. C., Iafrate, A. J., et al. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31826885fb · Cited by 173 · see citing works

Surgical implications of the new IASLC/ATS/ERS adenocarcinoma classification

Schil, P. E. V., Asamura, H., Rusch, V. W., Mitsudomi, T., Tsuboi, M., Brambilla, E. M., & Travis, W. D. (2011) · European Respiratory Journal · doi:10.1183/09031936.00027511 · Cited by 170 · see citing works

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1 -Rearranged Lung Cancer

Drilon, A. E. D. C., Somwar, R., Wagner, J. P., Vellore, N. A., Eide, C. A., Zabriskie, M. S., Arcila, M. E., Hechtman, J. F., Wang, L., Smith, R. S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2013 · Cited by 169 · see citing works

Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib

Gainor, J. F., Sherman, C. A., Willoughby, K., Logan, J., Kennedy, E., Brastianos, P. K., Chi, A. S., & Shaw, A. T. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000455 · Cited by 168 · see citing works

Estimating Overdiagnosis in Low-Dose Computed Tomography Screening for Lung Cancer

Veronesi, G., Maisonneuve, P., Bellomi, M., Rampinelli, C., Durli, I., Bertolotti, R., & Spaggiari, L. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-11-201212040-00005 · Cited by 160 · see citing works

Alectinib Shows Potent Antitumor Activity against RET -Rearranged Non–Small Cell Lung Cancer

Kodama, T., Tsukaguchi, T., Satoh, Y., Yoshida, M., Watanabe, Y., Kondoh, O., & Sakamoto, H. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0274 · Cited by 158 · see citing works

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches

Shea, M., Costa, D. B., & Rangachari, D. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815617871 · Cited by 157 · see citing works

Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations

Kinno, T., Tsuta, K., Shiraishi, K., Mizukami, T., Suzuki, M., Yoshida, A., Suzuki, K., Asamura, H., Furuta, K., Kohno, T., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt495 · Cited by 148 · see citing works

The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support

Warren, G. W., Sobus, S. L., & Gritz, E. R. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70266-9 · Cited by 147 · see citing works

A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib

Gautschi, O. P., Pauli, C., Strobel, K., Hirschmann, A., Printzen, G., Aebi, S. P., & Diebold, J. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182629903 · Cited by 141 · see citing works

Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?

Kerr, K. M., & Hirsch, F. R. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0522-sa · Cited by 134 · see citing works

Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers

Litvak, A. M., Paik, P. K., Woo, K. M., Sima, C. S., Hellmann, M. D., Arcila, M. E., Ladanyi, M., Rudin, C. M., Kris, M. G., & Riely, G. J. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000344 · Cited by 131 · see citing works

Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1 -Rearranged Non–Small Cell Lung Cancer

Song, A., Kim, T. M., Kim, D., Kim, S., Keam, B., Lee, S., & Heo, D. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1350 · Cited by 128 · see citing works

Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer

Scagliotti, G. V., Novello, S., Schiller, J. H., Hirsh, V., Sequist, L. V. D., Soria, J., von Pawel, J., Schwartz, B. E., von Roemeling, R., & Sandler, A. B. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.01.003 · Cited by 126 · see citing works

Why Do Pathological Stage IA Lung Adenocarcinomas Vary from Prognosis?: A Clinicopathologic Study of 176 Patients with Pathological Stage IA Lung Adenocarcinoma Based on the IASLC/ATS/ERS Classification

Zhang, J., Wu, J., Tan, Q., Zhu, L., & Gao, W. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829f09a7 · Cited by 123 · see citing works

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization

Ali, S. M., Hensing, T. A., Schrock, A. B., Allen, J. M., Sanford, E. M., Gowen, K. A., Kulkarni, A., He, J., Suh, J. H., Lipson, D., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0497 · Cited by 116 · see citing works

Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients—A single institution retrospective study of 292 lung adenocarcinoma

Gu, J., Lu, C., Guo, J., Chen, L., Chu, Y., Ji, Y., & Ge, D. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23259 · Cited by 112 · see citing works

Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis

Matsuo, Y., Chen, F., Hamaji, M., Kawaguchi, A., Ueki, N., Nagata, Y., Sonobe, M., Morita, S., Date, H., & Hiraoka, M. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.09.006 · Cited by 112 · see citing works

A Risk Model for Lung Cancer Incidence

Hoggart, C. J., Brennan, P., Tjønneland, A. M., Vogel, U. B., Overvad, K., Østergaard, J. N., Kaaks, R., Canzian, F., Boeing, H., Steffen, A., et al. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0237 · Cited by 110 · see citing works

Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients.

Planchard, D., Mazières, J., Riely, G. J., Rudin, C. M., Barlési, F., Quoix, É., Souquet, P. J., Socinski, M. A., Switzky, J. C., Ma, B., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8009 · Cited by 109 · see citing works

A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors.

Lutzky, J., Antonia, S. J., Blake-Haskins, A., Li, X., Robbins, P. B., Shalabi, A. M., Vasselli, J., Ibrahim, R. A., Khleif, S. N., & Segal, N. H. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3001 · Cited by 105 · see citing works

Dramatic Response Induced by Vemurafenib in a BRAF V600E-Mutated Lung Adenocarcinoma

Peters, S., Michielin, O. A., & Zimmermann, S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.6143 · Cited by 104 · see citing works

Tobacco Cessation May Improve Lung Cancer Patient Survival

Amato, K. A., Hyland, A. J., Reed, R., Mahoney, M. C., Marshall, J. R., Giovino, G. A., Bansal‐Travers, M., Ochs‐Balcom, H. M., Zevon, M. A., Cummings, K. M., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000578 · Cited by 103 · see citing works

A Patient with Lung Adenocarcinoma and RET Fusion Treated with Vandetanib

Gautschi, O. P., Zander, T., Aebersold, F., Strobel, K., Hirschmann, A., Aebi, S. P., & Diebold, J. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31828a4d07 · Cited by 100 · see citing works

The Correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) Classification With Prognosis and EGFR Mutation in Lung Adenocarcinoma

Yanagawa, N., Shiono, S., Abiko, M., Ogata, S., Satô, T., & Tamura, G. (2014) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2014.04.108 · Cited by 96 · see citing works

A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis

Downey, R. J., Ng, K., Kris, M. G., Bains, M. S., Miller, V. A., Heelan, R. T., Bilsky, M. H., Ginsberg, R. J., & Rusch, V. W. (2002) · Lung Cancer · doi:10.1016/s0169-5002(02)00183-6 · Cited by 94 · see citing works

Non–Small Cell Lung Cancer, PD-L1, and the Pathologist

Kerr, K. M., & Nicolson, M. C. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0303-sa · Cited by 92 · see citing works

Video-Assisted Thoracoscopic Lobectomy Versus Stereotactic Radiotherapy for Stage I Lung Cancer

Hamaji, M., Chen, F., Matsuo, Y., Kawaguchi, A., Morita, S., Ueki, N., Sonobe, M., Nagata, Y., Hiraoka, M., & Date, H. (2015) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2014.11.009 · Cited by 92 · see citing works

Emerging tobacco‐related cancer risks in C hina: A nationwide, prospective study of 0.5 million adults

Chen, Z., Peto, R., Iona, A., Yu, C., Chen, Y., Bian, Z., Yang, L., Zhang, W., Lu, F., Chen, J., et al. (2015) · Cancer · doi:10.1002/cncr.29560 · Cited by 91 · see citing works

BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib

Robinson, S. D., O’Shaughnessy, J., Cowey, C. L., & Konduri, K. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.05.009 · Cited by 91 · see citing works

The Master Protocol Concept

Redman, M. W., & Allegra, C. J. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.07.009 · Cited by 91 · see citing works

Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients

Michels, S., Scheel, A. H., Scheffler, M., Schultheis, A. M., Gautschi, O., Aebersold, F., Diebold, J., Pall, G., Rothschild, S., Bubendorf, L., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.09.016 · Cited by 91 · see citing works

Application of Risk Prediction Models to Lung Cancer Screening

Tammemägi, M. C. (2015) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000142 · Cited by 88 · see citing works

Prognostic value of the IASLC / ATS / ERS classification of lung adenocarcinoma in stage I disease of J apanese cases

Woo, T., Okudela, K., Mitsui, H., Tajiri, M., Yamamoto, T., Rino, Y., Ohashi, K., & Masuda, M. (2012) · Pathology International · doi:10.1111/pin.12016 · Cited by 88 · see citing works

Accuracy of the IASLC/ATS/ERS histological subtyping of stage I lung adenocarcinoma on intraoperative frozen sections

Bittar, H. E. T., Incharoen, P., Althouse, A. D., & Đačić, S. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.71 · Cited by 87 · see citing works

Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning

Ashraf, H., Dirksen, A., Loft, A., Bertelsen, A. K., Bach, K., Hansen, H., Pedersen, J. H., & Mortensen, J. (2010) · Thorax · doi:10.1136/thx.2010.136747 · Cited by 87 · see citing works

Predictive Accuracy of the PanCan Lung Cancer Risk Prediction Model -External Validation based on CT from the Danish Lung Cancer Screening Trial

Wille, M. M. W., van Riel, S. J., Saghir, Z., Dirksen, A., Pedersen, J. H., Jacobs, C., Thomsen, L. H., Scholten, E. T., Skovgaard, L. T., & van Ginneken, B. (2015) · European Radiology · doi:10.1007/s00330-015-3689-0 · Cited by 83 · see citing works

Outcome of surgery versus radiotherapy after induction treatment in patients with N2 disease: systematic review and meta-analysis of randomised trials

McElnay, P., Choong, A. M. T. L., Jordan, E., Song, F., & Lim, E. K. S. (2015) · Thorax · doi:10.1136/thoraxjnl-2014-206292 · Cited by 83 · see citing works

Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients

Wang, R., Zhang, Y., Pan, Y., Li, Y., Hu, H., Cai, D., Li, H., Ye, T., Luo, X., Zhang, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5549 · Cited by 81 · see citing works

Identifying Targeted Strategies to Improve Smoking Cessation Support for Cancer Patients

Warren, G. W., Dibaj, S., Hutson, A. D., Cummings, K. M., Dresler, C. M., & Marshall, J. R. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000659 · Cited by 80 · see citing works

I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib

Ou, S. I., Greenbowe, J. R., Khan, Z. U., Azada, M. C., Ross, J. S., Stevens, P. J., Ali, S. M., Miller, V. A., & Gitlitz, B. J. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.02.005 · Cited by 80 · see citing works

Novel ALK fusion partners in lung cancer

Iyevleva, A. G., Раскин, Г. А., Tiurin, V. I., Соколенко, А. П., Mitiushkina, N. V., Алексахина, С. Н., Garifullina, A. R., Strelkova, T. N., Merkulov, V. O., Ivantsov, A. O., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.028 · Cited by 80 · see citing works

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma

Yeh, Y., Kadota, K., Nitadori, J., Sima, C. S., Rizk, N. P., Jones, D. R., Travis, W. D., & Adusumilli, P. S. (2015) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezv316 · Cited by 80 · see citing works

Screening for lung cancer using low dose computed tomography

Tammemägi, M. C., & Lam, S. C. (2014) · BMJ · doi:10.1136/bmj.g2253 · Cited by 78 · see citing works

Primary Study Endpoint Analysis for NRG Oncology/RTOG 0813 Trial of Stereotactic Body Radiation Therapy (SBRT) for Centrally Located Non-Small Cell Lung Cancer (NSCLC)

Bezjak, A., Paulus, R., Gaspar, L. E., Timmerman, R. D., Straube, W. L., Ryan, W. F., Garces, Y. I., Pu, A. T., Singh, A. K., Videtic, G. M. M., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.10.040 · Cited by 73 · see citing works

Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion–Positive Metastatic Non–Small-Cell Lung Cancer

Falchook, G. S., Ordóǹez, N. G., Bastida, C. C., Stephens, P. J., Miller, V. A., Gaido, L., Jackson, T. L., & Karp, D. D. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.5016 · Cited by 72 · see citing works

Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients—Based on a hospital study in China

Song, Z., Zhu, H., Guo, Z., Wu, W., Sun, W., & Zhang, Y. (2013) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2013.08.026 · Cited by 71 · see citing works

Delivering High-Quality and Affordable Care Throughout the Cancer Care Continuum

Shih, Y. T., Ganz, P. A., Aberle, D. R., Abernethy, A. P., Bekelman, J. E., Brawley, O. W., Goodwin, J. S., Hu, J. C., Schrag, D., Temel, J. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.0651 · Cited by 70 · see citing works

Customized Adjuvant Phase II Trial in Patients With Non–Small-Cell Lung Cancer: IFCT-0801 TASTE

Wislez, M., Barlési, F., Besse, B., Mazières, J., Merle, P., Cadranel, J. L., Audigier-Valette, C., Moro‐Sibilot, D., Gautier-Felizot, L., Goupil, F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1525 · Cited by 68 · see citing works

Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis.

Zhu, Q., Zhan, P., Zhang, X., Lv, T., & Song, Y. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2015.05.01 · Cited by 61 · see citing works

Positron emission tomography in the diagnostic work-up of screening-detected lung nodules

Veronesi, G., Travaini, L. L., Maisonneuve, P., Rampinelli, C., Bertolotti, R., Spaggiari, L., Bellomi, M., & Paganelli, G. (2014) · European Respiratory Journal · doi:10.1183/09031936.00066514 · Cited by 61 · see citing works

Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non–small-cell Lung Cancer Exhibiting Resistance to Ceritinib

Toyokawa, G., Inamasu, E., Shimamatsu, S., Yoshida, T., Nosaki, K., Hirai, F., Yamaguchi, M., Seto, T., Takenoyama, M., & Ichinose, Y. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000509 · Cited by 61 · see citing works

Diagnostic Performance of Low-Dose Computed Tomography Screening for Lung Cancer over Five Years

Veronesi, G., Maisonneuve, P., Spaggiari, L., Rampinelli, C., Pardolesi, A., Bertolotti, R., Filippi, N., & Bellomi, M. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000200 · Cited by 60 · see citing works

The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma

Zhang, Y., Li, J., Wang, R., Li, Y., Pan, Y., Cai, D., Hu, H., Li, H., Ye, T., Luo, X., et al. (2014) · Scientific Reports · doi:10.1038/srep07163 · Cited by 59 · see citing works

Surgical treatment of lung cancer in the octogenarians: results of a nationwide audit

Rivera, C., Dahan, M., Bernard, A., Falcoz, P., & Thomas, P. A. (2010) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2010.09.022 · Cited by 59 · see citing works

Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).

Sznol, M., Kluger, H. M., Hodi, F. S., McDermott, D. F., Carvajal, R. D., Lawrence, D. P., Topalian, S. L., Atkins, M. B., Powderly, J. D., Sharfman, W. H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.cra9006 · Cited by 58 · see citing works

Radical treatment of non-small cell lung cancer during the last 5 years

McCloskey, P., Balduyck, B., Schil, P. E. V., Finn, C. F., & O'Brien, M. E. R. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.023 · Cited by 57 · see citing works

Alectinib Induces a Durable (>15 Months) Complete Response in an ALK-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis

Ou, S. I., Sommers, K. R., Azada, M. C., & Garon, E. B. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0309 · Cited by 56 · see citing works

Magrit, a Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of the Recmage-A3 + As15 Cancer Immunotherapeutic As Adjuvant Therapy in Patients with Resected Mage-A3-Positive Non-Small Cell Lung Cancer (Nsclc)

Vansteenkiste, J., Cho, B. C., Vanakesa, T., Pas, T. M. D., Zielinski, M., Kim, M. S., Jassem, J., Yoshimura, M., Dahabreh, J., Nakayama, H., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu347.1 · Cited by 54 · see citing works

Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts).

Sequist, L. V. D., Goldman, J. W., Wakelee, H. A., Camidge, D. R., Yu, H. A., Varga, A., Solomon, B., Oxnard, G. R., Ou, S. I., Papadimitrakopoulou, V. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8001 · Cited by 54 · see citing works

Lung cancer: current therapies and new targeted treatments

Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L. L. C., & Paz-Ares, L. G. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30958-8 · Cited by 3,278 · see citing works

Tumor microenvironment complexity and therapeutic implications at a glance

Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784 · see citing works

Cell death-based treatment of lung adenocarcinoma

Denisenko, T. V., Budkevich, I. N., & Zhivotovsky, B. (2018) · Cell Death &amp; Disease · doi:10.1038/s41419-017-0063-y · Cited by 768 · see citing works

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Yuan, M., Huang, L., Chen, J., Wu, J., & Xu, Q. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0099-9 · Cited by 678 · see citing works

New and emerging targeted treatments in advanced non-small-cell lung cancer

Hirsch, F. R., Suda, K., Wiens, J., & Bunn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31473-8 · Cited by 493 · see citing works

TPGS‐Functionalized Polydopamine‐Modified Mesoporous Silica as Drug Nanocarriers for Enhanced Lung Cancer Chemotherapy against Multidrug Resistance

Cheng, W., Liang, C., Xu, L. S., Liu, G., Gao, N., Wei, T., Luo, L., Zuo, Y., Wang, X., Zhang, X., et al. (2017) · Small · doi:10.1002/smll.201700623 · Cited by 270 · see citing works

Epidemiological trends of tracheal, bronchus, and lung cancer at the global, regional, and national levels: a population-based study

Deng, Y., Zhao, P., Zhou, L., Xiang, D., Hu, J., Liu, Y., Ruan, J., Ye, X., Zheng, Y., Yao, J., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00915-0 · Cited by 260 · see citing works

The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable

Reungwetwattana, T., Liang, Y., Zhu, V. W., & Ou, S. I. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.11.011 · Cited by 173 · see citing works

Emerging therapies for non-small cell lung cancer

Zhang, C., Leighl, N. B., Wu, Y.-L. L. C., & Zhong, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0731-8 · Cited by 153 · see citing works

The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review

Meyer, E. L., Mesenbrink, P. G., Dunger‐Baldauf, C., Fülle, H., Glimm, E., Li, Y., Posch, M., & König, F. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.05.010 · Cited by 136 · see citing works

Small-molecule inhibition of APE1 induces apoptosis, pyroptosis, and necroptosis in non-small cell lung cancer

Long, K., Gu, L., Li, L., Zhang, Z., Li, E., Zhang, Y., He, L., Pan, F., Guo, Z., & Hu, Z. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03804-7 · Cited by 134 · see citing works

Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs

Choi, H. Y., & Chang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713618 · Cited by 139 · see citing works

Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

Cheng, Y., Zhang, T., & Xu, Q. (2021) · MedComm · doi:10.1002/mco2.105 · Cited by 125 · see citing works

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis

Liang, H., & Wang, M. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s231257 · Cited by 123 · see citing works

Systematic review of prognostic roles of body mass index for patients undergoing lung cancer surgery: does the ‘obesity paradox’ really exist?

Li, S., Wang, Z., Huang, J. V., Fan, J., Du, H., Liu, L., & Che, G. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw386 · Cited by 119 · see citing works

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer

Pan, Y., Deng, C., Qiu, Z., Cao, C., & Wu, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.713530 · Cited by 116 · see citing works

Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature

Norum, J., & Nieder, C. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000406 · Cited by 111 · see citing works

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity

Mittica, G., Ghisoni, E., Giannone, G., Aglietta, M., Genta, S., & Valabrega, G. (2017) · Oncotarget · doi:10.18632/oncotarget.20042 · Cited by 110 · see citing works

Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer

Chhouri, H., Alexandre, D., & Grumolato, L. (2023) · Cancers · doi:10.3390/cancers15020504 · Cited by 99 · see citing works

Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials

Collignon, O., Gärtner, C., Haidich, A., Hemmings, R. J., Hofner, B., Pétavy, F., Posch, M., Rantell, K. R., Roes, K. C. B., & Schiel, A. E. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1804 · Cited by 91 · see citing works

Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies

Koulouris, A., Tsagkaris, C., Corriero, A. C., Metro, G., & Mountzios, G. (2022) · Cancers · doi:10.3390/cancers14143337 · Cited by 99 · see citing works

Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies

Zhu, Q.-G., Zhang, S., Ding, X., He, B., & Zhang, H. (2017) · Oncotarget · doi:10.18632/oncotarget.17016 · Cited by 90 · see citing works

USP10 inhibits lung cancer cell growth and invasion by upregulating PTEN

Sun, J. Y., Li, T., Zhao, Y., Huang, L., Sun, H., Wu, H., & Jiang, X. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3170-2 · Cited by 85 · see citing works

Innovative Research Methods to Advance Precision in Home Visiting for More Efficient and Effective Programs

Supplee, L. H., & DUGGAN, A. K. (2019) · Child Development Perspectives · doi:10.1111/cdep.12334 · Cited by 85 · see citing works

Nanotechnology: Breaking the Current Treatment Limits of Lung Cancer

Li, S., Xu, S., Liang, X., Xue, Y., Mei, J., Ma, Y., Liu, Y., & Liu, Y. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100078 · Cited by 85 · see citing works

Aldolase A promotes proliferation and G 1 /S transition via the EGFR/MAPK pathway in non‐small cell lung cancer

Fu, H., Gao, H., Qi, X., Zhao, L., Wu, D., Bai, Y., Li, H., Liu, X., Hu, J. X., & Shao, S. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0290-3 · Cited by 80 · see citing works

Tumor molecular profiling of NSCLC patients using next generation sequencing

Τσούλος, Ν., Papadopoulou, E., Metaxa-Mariatou, V., Tsaousis, G., Efstathiadou, C., Tounta, G., Scapeti, A., Bourkoula, E., Zarogoulidis, P., Pentheroudakis, G. E., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.6051 · Cited by 75 · see citing works

CD38 knockout suppresses tumorigenesis in mice and clonogenic growth of human lung cancer cells

Bu, X., Kato, J., Hong, J. A., Merino, M. J., Schrump, D. S., Lund, F. E., & Moss, J. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx137 · Cited by 73 · see citing works

Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer

Zhu, V. W., Klempner, S. J., & Ou, S. I. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.09.008 · Cited by 73 · see citing works

Bone-marrow-derived cell-released extracellular vesicle miR-92a regulates hepatic pre-metastatic niche in lung cancer

Hsu, Y., Huang, M., Hung, J., Chang, W., Tsai, Y., Pan, Y., Lin, Y.-S., Tsai, H., & Kuo, P. (2019) · Oncogene · doi:10.1038/s41388-019-1024-y · Cited by 69 · see citing works

Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib

Veerman, G., Lam, M. H., Mathijssen, R. H. J., Koolen, S. L. W., & de Bruijn, P. (2019) · Journal of Chromatography B · doi:10.1016/j.jchromb.2019.03.011 · Cited by 62 · see citing works

Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma

Morgan, K. M., Fischer, B. S., Lee, F. Y., Shah, J. J., Bertino, J. R., Rosenfeld, J., Singh, A., Khiabanian, H., & Pine, S. R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0439 · Cited by 62 · see citing works

Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments—a systematic review

Olivares-Hernández, A., Portillo, E. G.-D., Tamayo-Velasco, Á., Figuero-Pérez, L., Zhilina-Zhilina, S., Fonseca‐Sánchez, E., & Miramontes‐González, J. P. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4218 · Cited by 66 · see citing works

Effects of Syringic Acid on Apoptosis, Inflammation, and AKT/mTOR Signaling Pathway in Gastric Cancer Cells

Pei, J., Velu, P., Zareian, M., Feng, Z., & Vijayalakshmi, A. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.788929 · Cited by 59 · see citing works

Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer

Dolly, S. O., Collins, D. C., Sundar, R., Popat, S., & Yap, T. A. (2017) · Drugs · doi:10.1007/s40265-017-0732-2 · Cited by 57 · see citing works

Application of CAD systems for the automatic detection of lung nodules

Shariaty, F., & Mousavi, M. (2019) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2019.100173 · Cited by 59 · see citing works

ALK and ROS1 testing on lung cancer cytologic samples: Perspectives

Pisapia, P., Lozano, M. D., Vigliar, E., Bellevicine, C., Pepe, F., Malapelle, U., & Troncone, G. (2017) · Cancer Cytopathology · doi:10.1002/cncy.21899 · Cited by 55 · see citing works

NUSAP1 knockdown inhibits cell growth and metastasis of non‐small‐cell lung cancer through regulating BTG2/PI3K/Akt signaling

Xu, Z., Wang, Y., Xiong, J., Cui, F., Wang, L., & Peng, H. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29282 · Cited by 55 · see citing works

Crizotinib: from discovery to accelerated development to front-line treatment

Blackhall, F. H., & Cappuzzo, F. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw304 · Cited by 53 · see citing works

Recommendations from the European Society of Thoracic Surgeons (ESTS) regarding computed tomography screening for lung cancer in Europe

Pedersen, J. H., Rzyman, W., Veronesi, G., D’Amico, T. A., Schil, P. E. V., Molins, L., Massard, G., & Rocco, G. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw418 · Cited by 53 · see citing works

The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer

Burgess, J. T., Rose, M., Boucher, D., Plowman, J., Molloy, C., Fisher, M. A., O’Leary, C. G., Richard, D. J., O'Byrne, K. J., & Bolderson, E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01256 · Cited by 53 · see citing works

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer

Takahashi, A., Seike, M., Chiba, M., Takahashi, S., Nakamichi, S., Matsumoto, M., Takeuchi, S., Minegishi, Y., Noro, R., Kunugi, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33190-8 · Cited by 51 · see citing works

Cancer cell-derived exosomes promote cell proliferation and inhibit cell apoptosis of both normal lung fibroblasts and non-small cell lung cancer cell through delivering alpha-smooth muscle actin.

Huang, J., Ding, Z., Luo, Q., & Xu, W. (2019) · Europe PMC (PubMed Central) · Cited by 52 · see citing works

Patterns of Extrathoracic Metastases in Different Histological Types of Lung Cancer

Wang, X., Wang, Z., Pan, J., Lu, Z., Xu, D., Zhang, H., Wang, S., Huang, D., & Chen, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00715 · Cited by 51 · see citing works

A systematic review and meta-analysis of the adequacy of endobronchial ultrasound transbronchial needle aspiration for next-generation sequencing in patients with non-small cell lung cancer

Zhao, J. J., Chan, H. P., Soon, Y. Y., Huang, Y., Soo, R. A., & Kee, A. C.-L. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.018 · Cited by 50 · see citing works

Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR

Zhang, Y., Xu, Y., Zhong, W., Zhao, J., Chen, M., Zhang, L., Li, L., & Wang, M. (2016) · Oncotarget · doi:10.18632/oncotarget.14390 · Cited by 49 · see citing works

Characterization of Liver Metastasis and Its Effect on Targeted Therapy in EGFR-mutant NSCLC: A Multicenter Study

Jiang, T., Cheng, R., Zhang, G., Su, C., Zhao, C., Li, X., Zhang, J., Wu, F., Chen, X., Gao, G., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.04.015 · Cited by 49 · see citing works

MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1

Jiang, F., Yu, Q., Chu, Y., Zhu, X., Lu, W., Liu, Q., & Wang, Q. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4610 · Cited by 46 · see citing works

Drug-sensitiveFGFR3 mutations in lung adenocarcinoma

Chandrani, P., Prabhash, K., Prasad, R., Sethunath, V., Ranjan, M., Iyer, P. S., Aich, J., Dhamne, H., Iyer, D. N., Upadhyay, P., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw636 · Cited by 46 · see citing works

Comparing CNN-based and transformer-based models for identifying lung cancer: which is more effective?

Gai, L., Xing, M., Chen, W., Zhang, Y., & Xu, Q. (2023) · Multimedia Tools and Applications · doi:10.1007/s11042-023-17644-4 · Cited by 48 · see citing works

Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)—from morphology to molecular testing

Righi, L., Franzi, F., Montarolo, F., Gatti, G., Bongiovanni, M., Sessa, F., & Rosa, S. L. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.03.158 · Cited by 42 · see citing works

The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer

Geva, S., Rozenblum, A. B., Twito, T., Grinberg, R., Dvir, A., Soussan‐Gutman, L., Ilouze, M., Roisman, L. C., Dudnik, E., Zer, A., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.101 · Cited by 43 · see citing works

Doxorubicin kinetics and effects on lung cancer cell lines using in vitro Raman micro‐spectroscopy: binding signatures, drug resistance and DNA repair

Farhane, Z., Bonnier, F., Howe, O. L., Casey, A., & Byrne, H. J. (2017) · Journal of Biophotonics · doi:10.1002/jbio.201700060 · Cited by 40 · see citing works

Distinct Prognostic Values of Alcohol Dehydrogenase Family Members for Non-Small Cell Lung Cancer

Wang, P., Zhang, L., Huang, C., Huang, P., & Zhang, J. (2018) · Medical Science Monitor · doi:10.12659/msm.910026 · Cited by 40 · see citing works

Axl-Targeted Delivery of the Oncosuppressor miR-137 in Non-small-Cell Lung Cancer

Nuzzo, S., Catuogno, S., Capuozzo, M., Fiorelli, A., Swiderski, P. M., Boccella, S., de Nigris, F., & Esposito, C. L. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.06.002 · Cited by 40 · see citing works

Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC

Friedlaender, A., Banna, G. L., Patel, S. H., & Addeo, A. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0675-9 · Cited by 40 · see citing works

Lung cancer in Brazil: epidemiology and treatment challenges

de Sá, V. D., Coelho, J., Capelozzi, V., & de Azevedo, S. D. (2016) · Lung Cancer · doi:10.2147/lctt.s93604 · Cited by 35 · see citing works

A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors

Qiu, Z., Fa, P., Liu, T., Prasad, C. B., Ma, S., Hong, Z., Chan, E. R., Wang, H., Li, Z., He, K., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0057 · Cited by 38 · see citing works

HMGB1 Enhances Drug Resistance and Promotes In Vivo Tumor Growth of Lung Cancer Cells

Zheng, H., Chen, J.-N., Yu, X. Y., Jiang, P., Yuan, L., Shen, H.-S., Zhao, L., Chen, P.-F., & Yang, M. (2016) · DNA and Cell Biology · doi:10.1089/dna.2016.3360 · Cited by 38 · see citing works

LINC‐PINT alleviates lung cancer progression via sponging miR‐543 and inducing PTEN

Wang, S., Jiang, W., Zhang, X., Lu, Z., Geng, Q., Wang, W., Li, N., & Cai, X. (2020) · Cancer Medicine · doi:10.1002/cam4.2822 · Cited by 38 · see citing works

Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies

da Veiga, C. R. P., da Veiga, C. P., & Drummond‐Lage, A. P. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.002 · Cited by 37 · see citing works

The emerging treatment landscape of advanced non-small cell lung cancer

Economopoulou, P., & Mountzios, G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.07 · Cited by 36 · see citing works

Development of an integrated CRISPRi targeting ΔNp63 for treatment of squamous cell carcinoma

Yoshida, M., Yokota, E., Sakuma, T., Yamatsuji, T., Takigawa, N., Ushijima, T., Yamamoto, T., Fukazawa, T., & Naomoto, Y. (2018) · Oncotarget · doi:10.18632/oncotarget.25678 · Cited by 36 · see citing works

Narrative review of molecular pathways of kinase fusions and diagnostic approaches for their detection in non-small cell lung carcinomas

Matter, M. S., Chijioke, O., Savic, S., & Bubendorf, L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-676 · Cited by 36 · see citing works

TMEM106A inhibits cell proliferation, migration, and induces apoptosis of lung cancer cells

Liu, J., & Zhu, H.-J. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28057 · Cited by 34 · see citing works

Neuregulin 1 Fusion–Positive NSCLC

Nagasaka, M., & Ou, S. I. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.015 · Cited by 35 · see citing works

Biological activity of Brassica rapa L. polysaccharides on RAW264.7 macrophages and on tumor cells

Wufuer, R., Bai, J., Liu, Z., Zhou, K., & Taoerdahong, H. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115330 · Cited by 35 · see citing works

Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets

Dalurzo, M. L., Avilés‐Salas, A., Soares, F. A., Hou, Y., Li, Y., Строганова, А. М., Öz, B., Abdillah, A., Wan, H., & Choi, Y. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s313669 · Cited by 39 · see citing works

The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: A systematic review with meta-analysis

Jiang, T., Zhai, C., Su, C., Ren, S., & Zhou, C. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.013 · Cited by 34 · see citing works

Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer

Liu, W., Zhang, L., Xiu, Z., Guo, J., Wang, L., Zhou, Y., Jiao, Y., Sun, M., & Cai, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s255491 · Cited by 34 · see citing works

Nf1 loss promotes Kras-driven lung adenocarcinoma and results in Psat1-mediated glutamate dependence

Wang, X., Min, S., Liu, H., Wu, N., Liu, X., Wang, T., Li, W., Shen, Y., Wang, H., Qian, Z., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809856 · Cited by 33 · see citing works

Temporal trends of tracheal, bronchus, and lung cancer between 2010 and 2019, in Asian countries by geographical region and sociodemographic index, comparison with global data

Rezaei, F., Mazidimoradi, A., Rayatinejad, A., Allahqoli, L., & Salehiniya, H. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.14912 · Cited by 32 · see citing works

Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase ( ALK )‐rearranged non‐small cell lung cancer

Zhou, X., Shou, J., Jin, S., Xu, C., Ren, S., Cai, X., Chu, Q., Wang, W., Zhen, Q., Zhou, Y., et al. (2019) · Cancer Science · doi:10.1111/cas.14177 · Cited by 32 · see citing works

Nanoscale Formulations: Incorporating Curcumin into Combination Strategies for the Treatment of Lung Cancer

Wu, Q., Ou, H., Shang, Y., Zhang, X., Wu, J., & Fan, F. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s311107 · Cited by 32 · see citing works

Next-Generation Sequencing (NGS)

Wang, M. (2021) · Springer eBooks · doi:10.1007/978-981-16-1037-0_23 · Cited by 31 · see citing works

Trends in age- and sex-specific lung cancer mortality in Europe and Northern America: Analysis of vital registration data from the WHO Mortality Database between 2000 and 2017

Baum, P., Winter, H., Eichhorn, M., Rösch, R., Taber, S., Christopoulos, P., Wiegering, A., & Lenzi, J. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.011 · Cited by 31 · see citing works

Anti-tumor effects of combined doxorubicin and siRNA for pulmonary delivery

Xu, C., Tian, H., Wang, Y.-B., Du, Y., Chen, J., Lın, L., Guo, Z., & Chen, X. (2016) · Chinese Chemical Letters · doi:10.1016/j.cclet.2016.12.013 · Cited by 30 · see citing works

ADAMTS-1 inhibits angiogenesis via the PI3K/Akt-eNOS-VEGF pathway in lung cancer cells

Wang, B., Chen, S., Zhao, J.-Q., Xiang, B., Gu, X., Zou, F., & Zhang, Z.-H. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.10.34 · Cited by 30 · see citing works

Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations

Joshi, A., Mishra, R., Desai, S., Chandrani, P., Kore, H., Sunder, R., Hait, S., Iyer, P. S., Trivedi, V., Choughule, A. B., et al. (2021) · Oncotarget · doi:10.18632/oncotarget.27905 · Cited by 30 · see citing works

Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung

Hirai, A., Yoneda, K., Shimajiri, S., Kuroda, K., Hanagiri, T., Fujino, Y., & Tanaka, F. (2017) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2017.05.106 · Cited by 29 · see citing works

Recent advances in the management of non-small cell lung cancer

Shojaee, S., & Nana-Sinkam, P. S. (2017) · F1000Research · doi:10.12688/f1000research.11471.1 · Cited by 29 · see citing works

Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay

Hou, H., Yang, X., Zhang, J., Zhang, Z., Xu, X., Zhang, X., Zhang, C., Liu, D., Yan, W., Zhu, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14962-0 · Cited by 28 · see citing works

Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Blood–Brain Barrier

Angeli, E., & Bousquet, G. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091446 · Cited by 29 · see citing works

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease

Marinelli, D., Siringo, M., Metro, G., Ricciuti, B., & Gelibter, A. J. (2022) · Drugs in Context · doi:10.7573/dic.2022-3-1 · Cited by 29 · see citing works

miR-98 inhibits expression of TWIST to prevent progression of non-small cell lung cancers

Zhou, H., Huang, Z., Chen, X., & Chen, S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.012 · Cited by 27 · see citing works

Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer

Qvick, A., Stenmark, B., Carlsson, J., Isaksson, J., Karlsson, C., & Helenius, G. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00331-1 · Cited by 26 · see citing works

Prognostic significance of minichromosome maintenance mRNA expression in human lung adenocarcinoma

Li, S., Jiang, Z., Li, Y., & Xu, Y. (2019) · Oncology Reports · doi:10.3892/or.2019.7330 · Cited by 26 · see citing works

Clinical and Genetic Implications of Mutation Burden in Squamous Cell Carcinoma of the Lung

Okamoto, T., Takada, K., Sato, S., Toyokawa, G., Tagawa, T., Shoji, F., Nakanishi, R., Oki, E., Koike, T., Nagahashi, M., et al. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6401-1 · Cited by 25 · see citing works

Next Generation Sequencing of Advanced Non–Small Cell Lung Cancer: Utilization Based on Race and Impact on Survival

Alahmadi, A. A., Ardeshir‐Larijani, F., Fu, P., Cao, S., Lipka, M. B., Dowlati, A., & Bruno, D. S. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.08.004 · Cited by 25 · see citing works

The impact of immunohistochemistry on the classification of lung tumors

Pelosi, G., Scarpa, A., Forest, F., & Sonzogni, A. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1235975 · Cited by 25 · see citing works

Nanomedicine initiates ferroptosis for enhanced lung cancer therapy

Xu, Y., Zhang, K., Ye, Z., Huang, Z., Chen, R., Zhang, Y., Zhang, H., & Kou, L. (2025) · Drug Delivery · doi:10.1080/10717544.2025.2527752 · Cited by 25 · see citing works

Shenfu Injection Adjunct with Platinum‐Based Chemotherapy for the Treatment of Advanced Non‐Small‐Cell Lung Cancer: A Meta‐Analysis and Systematic Review

Cao, A., He, H., Jing, M., Yu, B., & Zhou, X. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/1068751 · Cited by 24 · see citing works

Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing

Prabhash, K., Advani, S. H., Batra, U., Biswas, B., Chougule, A., Ghosh, M., Muddu, V. K., Sahoo, T. P., & Vaid, A. K. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00903-y · Cited by 24 · see citing works

PPARα ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis

Wu, L., Wang, W., Dai, M., Li, H., Chen, C., & Wang, D. W. (2019) · BMC Cancer · doi:10.1186/s12885-019-6379-5 · Cited by 24 · see citing works

Has aidi injection the attenuation and synergistic efficacy to gemcitabine and cisplatin in non-small cell lung cancer? A meta-analysis of 36 randomized controlled trials

Xiao, Z., Wang, C.-Q., Ling, C., Tang, X., Li, L., Li, N., Li, J., Gong, Q., Tang, F., Feng, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13617 · Cited by 23 · see citing works

Nuclear Pyruvate Kinase M2 (PKM2) Contributes to Phosphoserine Aminotransferase 1 (PSAT1)-Mediated Cell Migration in EGFR-Activated Lung Cancer Cells

Biyik‐Sit, R., Kruer, T. L., Dougherty, S. M., Bradley, J. A., Wilkey, D. W., Merchant, M. L., Trent, J. O., & Clem, B. F. (2021) · Cancers · doi:10.3390/cancers13163938 · Cited by 23 · see citing works

Advances in Treatment of Locally Advanced or Metastatic Non–Small Cell Lung Cancer

Giustini, N., Jeong, A., Buturla, J. A., & Bazhenova, L. A. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2020.02.003 · Cited by 23 · see citing works

The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions

Qin, A., & Gadgeel, S. M. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0526-1 · Cited by 22 · see citing works

Development of an updated, standardized, patient-centered outcome set for lung cancer

de Rooij, B. H., van den Hurk, C. J. G., Smaardijk, V. R., Fernández‐Ortega, P., Navarro-Martín, A., Barberio, L., Gückenberger, M., Schmid, S., Walraven, I., Vallow, S., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.08.021 · Cited by 22 · see citing works

The computer in clinical research and anaesthesia

Cohen, A. T., & Webster, N. R. (1988) · Baillière s Clinical Anaesthesiology · doi:10.1016/s0950-3501(88)80030-8

Lung Cancer

Passiglia, F., Gristina, V., Rolfo, C. D., Barraco, N., Bazan, V., & Russo, A. D. (2021) · UNIPA Springer series · doi:10.1007/978-3-030-56051-5_32

Lung cancer: biology and technology foster therapeutic innovation

Mountzios, G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.19 · Cited by 3 · see citing works

Lung cancer immunotherapy: progress, pitfalls, and promises

Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A., & Paul, M. K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01740-y · Cited by 1,102 · see citing works

JTO Clinical and Research Reports Is Born

Adjei, A. A. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100014 · Cited by 1 · see citing works